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Abstract
Background: In many GAVI-eligible countries, effectiveness of new vaccines will be evaluated by case-control
methodology. To inform the design and assess selection bias of a future case-control study of rotavirus vaccine
effectiveness (VE) in western Kenya, we performed a sham case-control study evaluating VE of pentavalent vaccine
(DTP-Hib-HepB) against rotavirus acute gastroenteritis (AGE).
Methods: From ongoing rotavirus surveillance, we defined cases as children 12 weeks to 23 months old with
EIA-confirmed rotavirus AGE. We enrolled one community-based and two hospital-based control groups. We
collected vaccination status from cards at enrollment, or later in homes, and evaluated VE by logistic regression.
Results: We enrolled 91 cases (64 inpatient, 27 outpatient), 252 non-rotavirus AGE facility-based controls (unmatched),
203 non-AGE facility-based controls (age-matched) and 271 community controls (age-matched). Documented receipt
of 3 pentavalent doses was 77% among cases and ranged from 81-86% among controls. One percent of cases
and 0-2% of controls had no pentavalent doses. The adjusted odds ratio of three versus zero doses for being a
case was 3.27 (95% CI 0.01-1010) for community controls and 0.69 (95% CI 0.06-7.75) for non-rotavirus hospital-based
AGE controls, translating to VE of −227% and 31%, respectively, with wide confidence intervals. (No facility-based
non-AGE controls were unvaccinated.) Similar results were found for ≥2 pentavalent doses and for severe rotavirus AGE.
Conclusions: The study showed that it is feasible to carry out a real case control in the study area, but this needs to be
done as soon as the vaccine is introduced to capture the real impact. Sham case-control or pilot studies before vaccine
introduction can be useful in designing case-control VE studies.
Keywords: Rotavirus, Case-control, Vaccine effectiveness
Background
Rotavirus causes approximately 453,000 deaths annually
in children, most of them occurring in sub-Saharan
Africa and Asia [1]. By December 2012, 13 of 73 coun-
tries eligible for funding through the Global Alliances
for Vaccines and Immunizations (GAVI) had introduced
rotavirus vaccines into their national immunization
programs and 20 more countries, including Kenya, had
been approved to receive GAVI funding for rotavirus
vaccine [2,3].
As more developing countries introduce rotavirus vac-
cines, there is growing interest in evaluating their impact
to support decisions for continued and augmented
country-level financing. In many countries with on-going
rotavirus surveillance, rotavirus vaccine effectiveness (VE)
will be evaluated by case-control methodology [4-6].
Case-control studies for evaluation of VE have the advan-
tage of being relatively quick, not requiring pre-vaccine
data or a well-defined denominator population, and being
efficient in the setting of rare diseases [6,7]. Case-control
studies have been utilized to evaluate rotavirus VE in
Nicaragua and El Salvador [8-10], as well as other vaccines
in various settings [7,11-13]. While having advantages,
case-control studies are inherently at risk of selection bias
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due to the challenges of selecting a sample of controls
representative of the population from which the cases
arose [7,14,15]. If controls differ in their propensity to
be vaccinated or to seek medical care from the source
population of cases, then the association between vaccine
and disease can be distorted, leading to biased estimates
of VE [7,16]. Besides selection bias, case-control studies
can suffer from misclassification of exposure (i.e. vac-
cination status).
We used ongoing surveillance for rotavirus gastroenteritis
in rural western Kenya to perform a case-control study
evaluating effectiveness of pentavalent vaccine (diphtheria,
pertussis, tetanus Haemophilus influenzae type b (Hib), and
hepatitis B) on rotavirus gastroenteritis. Since pentavalent
vaccine should have no protection against rotavirus disease,
we refer to this study as a “sham” case-control study, and
as such, after adjusting for potential confounders, any
“vaccine effectiveness” could be ascribed to residual
selection bias, and could be useful in interpreting results
of a real case-control study of rotavirus VE undertaken
after the vaccine’s introduction into Kenya. Besides
assessing selection bias, our study aimed to define char-
acteristics of the population (e.g. vaccine coverage and
timeliness) and the design (e.g. ability to document
vaccine status) that would inform the design and execu-
tion of a real case-control study of rotavirus vaccine
after its introduction into Kenya.
Methods
Rotavirus surveillance
The study was conducted in Siaya County, western
Kenya, in the setting of a long-standing Health and
Demographic Surveillance System (HDSS) [17]. The area
is rural, poor, has high malaria and HIV prevalence, and
a high under-5 mortality ratio [17-19].
Surveillance for acute gastroenteritis (AGE) among
children <5 years of age was conducted among inpatients
at a district hospital and outpatients at two health centers
located in the HDSS area. AGE was defined as ≥3 looser
than normal stools and/or >1 episode of unexplained
vomiting followed by loose stool within a 24-hour period
beginning within seven days before seeking healthcare.
Stool was collected in a plastic diaper from which at least
2 ml of stool was scooped into a specimen container. In
the outpatient facilities, if the child was unable to pro-
vide stool during the visit, a field worker would follow-
up at the child’s home to collect stool. All stool samples
were collected within 48 hours after presentation,
stored and transported in cool boxes on the same day
of collection to KEMRI/CDC laboratories, approxi-
mately 60 kilometers away. Batch testing for rotavirus
using enzyme-immunoassay (EIA, Rotaclone™ Kit) was
done.
Case-control study
The case-control study was embedded in ongoing rota-
virus surveillance system. Eligible children were 12 weeks
(i.e. 2 weeks after the second scheduled Expanded
Program for Immunization visit) to 23 months of age
who presented with AGE, as these children are eligible
to have received pentavalent vaccine. Among these,
cases were defined as those with an EIA-confirmed
rotavirus-positive stool sample. Severe AGE was defined
using the 20-point numerical Vesikari scoring system
with scores of ≥11 [20]. Case selection at the sites was
consecutive until the desired sample size was reached.
Inpatients were enrolled continuously, including during
nights and weekends. Outpatients were enrolled during
weekday daytime hours.
We enrolled two hospital and one community-based
control groups. The first hospital control group was
unmatched, consisting of children presenting to the same
facility as the cases, who had AGE not caused by rotavirus,
as determined by a negative rotavirus EIA test. The
second hospital control group was children presenting
with a non-AGE illness, excluding those who had other
EPI-vaccine-preventable diseases (i.e. measles, pneumonia,
meningitis, sepsis, otitis media, bacteraemia, epiglottitis,
hepatitis and pertussis). In a 3:1 ratio, controls were
age-matched to cases within −15 to +60 days of the
case-patient’s birthday. Eligible controls were enrolled
starting from the admission closest in date to the case’s
admission date, until three controls were enrolled. The
third control group was selected from the same villages
as the case-patients, but not living in the same compound.
Starting at the case’s compound, we went to the nearest
compound on either side of the case’s compound to check
for eligible children. If no children met eligibility criteria
in that compound, we went to the adjacent compound in
the same direction until we enrolled a control. After the
first control, we skipped the next compound and inquired
about eligible controls at the following compound. We
repeated this process until we enrolled three controls.
HIV testing
HIV testing was done using parallel rapid test kits on whole
blood obtained from finger-prick –Determine HIV-1/2
(Abbott Diagnostic Division, Hoofdorp, Netherlands)
and Bioline® (Standard Diagnostics Inc, Korea) - with
tie-breaking of discordant results using Unigold™ (Trinitiy
Biotech PLC, Ireland). PCR testing confirmed HIV status
for children <18 months old who were antibody-positive
on at least one rapid test.
Data collection
During an interview with trained study staff, the parent
was asked for each child’s Ministry of Health-issued
vaccination card. For children who came to the hospital
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without their vaccination card, we visited their home
and collected the immunization history from available
cards. If the card was not available, a verbal report of
the child’s vaccination status was collected. Other data
collected included history, symptoms and signs of
illness for cases, parent’s education level, household
characteristics and possessions, and distance to the
nearest health facility.
Sample size
For the sham case-control study, we did not expect to
find statistically significant “effectiveness” of the pentava-
lent vaccine against rotavirus AGE, but rather to deter-
mine if the study found a point estimate that gave an
indication of potential bias (i.e. the odds ratio was
significantly different from 1.0). To estimate enrollment
duration for a real case-control study, we determined
the sample size based on a rotavirus VE evaluation.
While coverage with two Pentavalent doses is 94% in the
area [21], we assumed that in the first year of rotavirus
vaccine introduction, coverage among infants would be
lower due to obstacles of rolling out the vaccine. We
therefore estimated 50% coverage. Using these parameters,
we needed 61 cases and183 controls in each of the three
control groups (3:1 control to case ratio) to detect a VE of
60% in the first year of life. To account for missing data,
we increased the sample size by 10%, to 67 cases and 201
controls per control group.
Data analysis
A dose of pentavalent was considered valid (i.e. immuno-
logically protective) if it was administered ≥14 days before
the date of admission for the case, 14 days before the date
of admission for the case for the matched controls and
14 days before the control child’s admission for the
unmatched hospital controls.
To evaluate socioeconomic status (SES), we constructed
quintiles based on eight indicator variables of asset
ownership which were scored and reduced to a single
score through principal component analysis [22]. We
19
Number of children <5 yrs admitted at 
the Inpatient facility
N=2,254
Number of children <5yrs seen at the 
Outpatient facilities
N=1986
n (%) AGE <5 yrs admitted at facility
504 (22)
n (%) AGE <5 yrs seen at the outpatient
232 (12)
n (%) AGE 3-23 months admitted
409 (81) 
n (%) AGE 3-23 months seen
176 (76)
n (%) AGE 3-23 months admitted with 
stool collected
289 (71)
n (%) AGE 3-23 months seen with
stool collected
118 (67)
n (%) rotavirus positive and had been 
screened for case-control study
80 (28)
n (%) rotavirus positive and had been 






16 (20%) refusal 5 (16%) refusal
n (%)Stool not collected 
120(29)




Unable to produce/collect 
stool=106
n (%)Stool not collected 
58(33)
Reasons for not collecting
Transferred/Absconded=4
Refusal=4
Unable to produce/collect 
stool=50
Figure 1 Flow chart of rotavirus surveillance and enrollment of cases in case–control study from December 2010 to November 2011.
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considered risk factors for rotavirus AGE using commu-
nity controls only because comparison between cases and
the two hospital control groups evaluated rotavirus AGE
risk against other diagnoses, which has less meaningful
epidemiologic interpretation. Comparison between rota-
virus AGE cases and hospital controls was done only to
identify variables for adjustment in logistic regression.
The primary analysis included only documented reports
of vaccine status; having zero doses was determined from
either vaccination card or verbal report as it was expected
that unvaccinated children may be less likely to have
cards, which are usually given at the first vaccination in
the clinic. The main analysis compared children who had
received three doses versus zero doses. Secondary analyses
included children who had received at least two docu-
mented doses versus zero doses. For the analysis of the
matched control groups, conditional logistic regression
was used; all variables with a p value of <0.10 in univariate
analysis were incorporated in multivariable analysis using
backwards elimination. Variables with more than 5%
unknown responses were included in the model with
“unknown” coded as a category of a dummy variable. Chil-
dren with unknown vaccine status were always excluded
from the model. VE was calculated as ((1-Odds Ratio)
X 100). We also did an unmatched analysis of cases and
non-rotavirus facility-based AGE controls, controlling for
age in months and seasonality (4 quarters of the year)
using unconditional logistic regression. We reran the
analysis for only severe cases. Lastly, we evaluated timely
vaccination, defined as having received the vaccine be-
tween one week before and two weeks after the scheduled
date of vaccination, which in Kenya is 6, 10 and 14 weeks
for the primary EPI series.
Ethical considerations
This study was approved by the Kenya Medical Research
Institute’s ethics review committee (SSC#1836). Written
informed consents were obtained from all participants
or their legal guardians prior to enrolment.
Results
Case enrollment occurred from December 1, 2010
through November 30, 2011. There were 507 AGE hos-
pitalizations among children <5 years old and 232 AGE
sick visits in the outpatient facilities, of which, 409 (81%)
and 176 (76%) were among children 3–23 months of
age, respectively (Figure 1). We obtained stool speci-
mens from 289 (71%) age-eligible inpatients and 118
(67%) age-eligible outpatients. Severe AGE occurred in
197 (68%) inpatients and 35 (30%) outpatients (Table 1).
Among inpatients, stool samples were more likely to be
collected from children <12 months of age and with
severe AGE (Table 1). No difference in stool collection
was seen among outpatients. Among the 3–23 month
old inpatients and outpatients with AGE who had stool
collected, 80 (28%) and 32 (27%), respectively, were
positive for rotavirus (Figure 1). Five (6%) hospitalized
rotavirus-positive cases died during their admission.
Among age-eligible rotavirus AGE cases, 64 (80%) inpa-
tients and 27 (84%) outpatients were enrolled (Figure 1).
We enrolled 252 AGE hospital controls without rota-
virus detected, 203 non-AGE hospital controls and 271
Table 1 Characteristics of children with AGE with and without stool collection, western Kenya, 2010-11
Inpatients with AGE (n = 409) Outpatients with AGE (n = 176)
Stool collected, n (%) Stool not collected, n (%) P value Stool collected, n (%) Stool not collected, n (%) P value
Age
3-11 months 196 (68) 67 (56) 0.02 78 (66) 31 (53) 0.10
12–23 months 93 (32) 53 (44) 40 (34) 27 (47)
Sex
Male 160 (55) 59 (49) 0.25 71 (60) 29 (50) 0.20
Female 129 (45) 61 (51) 47 (40) 29 (50)
Vesikari score
≥11 197 (68) 68 (57) 0.03 35 (30) 18 (31) 0.85
<11 92 (32) 52 (43) 83 (70) 40 (69)
HIV status
Positive 18 (6) 9 (8) 0.17 2 (2) 0 (0) 0.58
Negative 227 (79) 84 (70) 53 (45) 28 (48)
Unknown 44 (15) 27 (22) 63 (53) 30 (52)
HDSS resident
Yes 183 (63) 68 (57) 0.21 116 (98) 55 (95) 0.15
No 106 (37) 52 (43) 1 (1) 3 (5)
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controls (N = 271)
Hospital non-AGE
controls (N = 203)
Hospital non-rotavirus
AGE controls (N = 252)












Male 53 (58) 136 (50) 0.26 102 (50) 0.34 135 (54) 0.44
Age in monthsb
3–5 31 (34) 67 (25) Matched 47 (23) Matched 60 (24) ref
6–11 36 (40) 120 (44) 92 (45) 96 (38) 0.28
12–17 16 (18) 47 (17) 47 (23) 58 (23) 0.08
19-23 8 (9) 37 (14) 17 (8) 38 (15) 0.05
Mother ≤ primary
education
66 (74) 222 (82) 0.10 161 (80) 0.16 204 (82) 0.14
Father ≤ primary
educationc
39 (43) 174 (64) <0.01 0.32
(0.16 – 0.68)
102 (50) 0.02 0.30
(0.13 – 0.70)




68 (76) 229 (85) 0.08 0.15
(0.04 – 0.66)
167 (83) 0.08 0.30
(0.10 – 0.87)
210 (83) 0.15 0.31
(0.14 – 0.66)
≤ 30 minutes to
health facilityc
48 (53) 127 (47) 0.53 102 (50) 0.17 115 (46) 0.29
SES quintile
Poorest 17 (20) 80 (30) <0.001 1 41 (21) ref 1 45 (18) ref
Poorer 6 (7) 58 (22) 0.75
(0.24 – 2.34)
34 (17) 0.15 0.17
(0.04 – 0.76)
53 (21) 0.02
Poor 12 (14) 56 (21) 0.96
(0.36 – 2.56)
32 (16) 0.62 0.54
(0.17 – 1.78)
47 (19) 0.36
Less poor 34 (40) 48 (18) 2.54
(1.11 – 5.85)
54 (27) 0.38 1.27
(0.46 – 3.50)
65 (27) 0.36
Least poor 17 (20) 25 (9) 2.00
(0.75 – 5.35)
38 (19) 0.91 0.56
(0.16 – 1.97)
34 (11) 0.50
HIV positive 3 (3) 5 (2) 0.01 7 (3) ref 15 (6) Ref
HIV negative 64 (70) 231 (85) 160 (79) 0.54 164 (65) 0.30
HIV unknown 24 (26) 35 (13) 36 (18) 0.45 73 (29) 0.46
Born
prematurelyc




Tap 9 (10) 13 (5) 0.03 17 (8) ref 7 (3) ref 1
Unprotected
spring
33 (32) 80 (30) 76 (37) 0.43 84 (33) 0.03 0.23
(0.07 – 0.75)
River/stream 38 (42) 118 (44) 73 (36) 0.34 114 (45) 0.01 0.21
(0.07 – 0.66)









84 (92) 219 (82) 0.01 4.14
(1.41 – 12.15)
192 (95) 0.83 224 (89) 0.36
Season
Jan-Mar 54 (59) 164 (61) Matched 130 (64) Matched 95 (38) ref 1
Apr-Jun 20 (22) 55 (20) 42 (21) 101 (40) <0.01 0.27
(0.14 – 0.52)
Jul-Sep 10 (11) 31 (11) 12 (6) 29 (12) 0.22 0.63
(0.27 – 1.46)
Khagayi et al. BMC Infectious Diseases 2014, 14:77 Page 5 of 10
http://www.biomedcentral.com/1471-2334/14/77
community controls. In multivariable analysis, comparing
rotavirus AGE cases to community controls having a
father with less education , a mother currently married,
and being moderately-to-severely stunted were protective
against being a case, while being in the least poor SES
quintiles and not attending daycare were significant risk
factors (Table 2).
The percentage of cases with documented vaccination
status was 83%, which was lower than among community
controls (90%) and higher than hospital controls (74-77%).
Among cases, 77% had received 3 doses of pentavalent by
documented report and only 1% were unvaccinated
(Table 3). Among control groups, this proportion with 3
doses varied slightly – 86% for community controls, 81%
for facility-based non-AGE controls, and 83% for un-
matched facility-based AGE controls, according to the
vaccine card with only 0% - 2% unvaccinated.
The adjusted odds ratio of three doses versus zero
doses was 3.27 (95% CI 0.01-1010) for community con-
trols and 0.69 (95% CI 0.06-7.75) for facility-based AGE
controls; this translates to VE of −227% and 31%, re-
spectively, with very wide confidence intervals (Table 4).
(No facility-based non-AGE controls were unvaccinated,
thus this analysis could not be performed.) Similar results
were found when evaluating ≥2 doses of pentavalent vac-
cine versus zero doses and when restricting cases to
severe rotavirus AGE (Table 4).
Among cases with documented timing of pentavalent
immunization, 83%, 70% and 69% received timely vac-
cination for pentavalent doses 1, 2 and 3, respectively
(Figure 2). Similar timing of vaccination was seen among
all control groups.
Discussion
Our sham case-control study provided several important
lessons that can be applied to a case-control study of
rotavirus VE in the same setting after vaccine introduc-
tion, expected in 2014 [2]. First and foremost, a major
challenge was finding very few unvaccinated children,
which limited the study’s power to make any conclusions
about bias. Given the high coverage levels of routine
immunizations in Kenya, unvaccinated children may not
be epidemiologically representative of children in this
population. An evaluation of rotavirus VE in Nicaragua
found that small differences in vaccine coverage resulted
in substantially disparate estimates of VE when coverage
was high (≥95% vaccinated), but not when coverage was
lower (~91% vaccinated) [23]. To avoid this problem in
Kenya, we plan to perform the case-control study of
rotavirus vaccine during the roll-out phase before full
coverage is achieved.
Although case-control studies often employ multiple
control groups in an attempt to understand bias, multiple
control groups often yield varying effectiveness estimates,
Table 2 Univariate analysis comparing risk factors among rotavirus AGE cases and controls, western Kenya, 2010-11
(Continued)
Oct-Dec 7 (7) 20 (7) 19 (9) 27 (11) 0.09 0.39
(0.15 – 1.05)
Underweight
Normal 77 (84) 212 (78) 0.15 154 (76) ref 1 181 (72) ref
Moderate 10 (11) 37 (14) 18 (9) 0.72 0.57
(0.17 – 1.93)
29 (12) 0.59




Normal 64 (70) 119 (44) <0.01 1 128 (63) ref 160 (63) ref
Moderate 12 (13) 54 (20) 0.60
(0.25 – 1.46)
33 (16) 0.35 41 (16) 0.39
Severe 15 (16) 98 (36) 0.19
(0.08 – 0.48)
42 (21) 0.05 51 (20) 0.35
Wasting
Normal 84 (92) 252 (93) 0.91 171 (84) ref 194 (77) ref
Moderate 4 (4) 8 (3) 14 (7) 0.34 21 (8) 0.14
Severe 3 (3) 11 (4) 18 (9) 0.12 37 (14) 0.01
aOnly variables that were significantly different between cases and controls, or of particular epidemiologic interest, are listed in tables. The following variables
were not significantly associated with case status: maternal age, number of children in household, fare to nearest facility, history of an AGE hospitalization,
enrollment in the HDSS, treats drinking water, and mother knows about ORS.
bTwo controls that were < 3 months old and three that were >23 months old, due to range of allowable matching ages were included in the 3–5 and 19–23 age
groups respectively.
c> 5% persons with missing or unknown responses included in multivariable analysis as a dummy variable (see methods).
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leaving researchers with challenges in interpretation of the
results. We explored three different source populations
for enrolling controls. Children in all three control groups
were largely similar to case-patients with regard to poten-
tially confounding socio-demographic characteristics. One
exception was that the hospitalized control groups tended
to have more severe malnutrition, suggesting children
hospitalized with non-rotavirus illnesses tend to be dif-
ferent in their nutritional status, which can potentially
confound VE estimates.
The ease of enrollment differed between the three
control groups. Matched non-AGE facility-based controls
were easy to enroll, but difficult to find sufficient numbers
to meet matching criteria and harder to collect vaccin-
ation data. Community control enrollment achieved
sufficient numbers, but required additional expense and
logistical coordination. Children hospitalized for AGE
who tested negative for rotavirus offered a time and
resource-efficient alternative to the other two more
traditional control groups, because they were already
being tested through the diarrheal surveillance plat-
form. These children had the same healthcare seeking
behavior for diarrheal illness as individuals with rota-
virus diarrhea, and had the most similar demographic
profile to rotavirus AGE cases, particularly SES which
can be related to health-seeking and vaccination. Add-
itionally, study staff were blinded to the child’s case or
control status at time of enrollment and during vaccine
verification, which occurred before EIA results were
available. The rotavirus EIA is highly sensitive and
specific and thereby minimizes the misclassification of
cases and controls [24-26]. Based on these reasons, we
believe in this setting the use of test-negative controls
will provide the most resource efficient and epidemio-
logically unbiased control group, and should be the
only control group for the real case-control study.
Another challenge was documenting vaccination status
and dates of vaccination. The proportion of children for
Table 4 Univariate and multivariable analysis comparing immunization status for rotavirus AGE cases versus controls,
western Kenya, 2010–11 (documented immunization status only)
Variablesa Community controls OR
(95% CI)
Hospital non-AGE controls OR
95% CI
Hospital AGE controlsc (unmatched)
OR 95% CI
Unadjusted OR Adjusted ORa Unadjusted OR Adjusted ORb Unadjusted OR Adjusted ORc
3 versus 0 pentavalent doses 1.00 (0.08 – 11.93) 3.27 (0.01 – 1010) Undefined Undefined 1.09 (0.11 – 10.66) 0.69 (0.06 – 7.75)
≥2 versus 0 pentavalent doses 0.77 (0.07 – 8.55) 2.26 (0.06 – 865) Undefined Undefined 1.15 (0.12 – 11.22) 0.64 (0.06 – 6.79)
Missing and unknown responses for variables were excluded in the regression.
aRegression with community controls adjusted for father’s education, mother’s marital status, socioeconomic status of household, child attends daycare
and stunting.
bRegression with hospital non-AGE controls adjusted for father’s education, mother’s marital status, socioeconomic status of household, child born prematurely,
child ever treated with ORS and underweight.
cRegression with hospital AGE controls adjusted for father’s education, mother’s marital status, season of the year and source of water.







Hospital AGE controls unmatched
(N = 252)
n (%) n (%) n (%) n (%)
Number of pentavalent doses receivedb
0 doses 1 (1) 3 (1) 0 (0) 3 (2)
1 dose 4 (5) 5 (2) 7 (5) 7 (4)
2 doses 12 (16) 25 (10) 20 (14) 23 (12)
3 doses 58 (77) 210 (86) 118 (81) 160 (83)
Of those with 2 doses of pentavalentc
Dose 2 received on time 47 (67) 152 (65) 89 (64) 121 (66)
Dose 2 not received on time 23 (33) 83 (35) 49 (36) 61 (34)
Of those with 3 doses of pentavalentc
Dose 3 received on time 30 (52) 117 (56) 61 (52) 90 (56)
Dose 3 not received on time 28 (48) 93 (44) 57 (48) 70 (44)
aFirst response to each variable was referent category in conditional logistic regression.
bA dose was considered given if it was given at least 14 days before the date of admission of the cases for cases and matched controls while for the unmatched
controls it was 14 days before their date of admission. Timely vaccination considered vaccination <1 before or >2 weeks after scheduled date of pentavalent2
pentavalent3 at 10 weeks and 14 weeks of age respectively.
cUnknown/missing responses not included.
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Figure 2 Distribution of age of vaccination for dose 1, 2 & 3 of pentavalent vaccine by cases and controls. a, b, c Vertical dotted line
represents scheduled date at 6, 10 & 14 weeks. Grey shaded area is considered timely vaccination.
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whom we were unable to document vaccination status
ranged from 10% in community controls to 29% in the
non-AGE hospital controls. High levels of undocumented
vaccination status could bias VE estimates particularly if
vaccination status is differentially missing by number of
doses received. For the real case-control study, efforts
will be made to seek documentation of vaccination for
all cases and controls in the home or the immunization
clinics, when unavailable in the hospital.
We did not find any significant associations of penta-
valent vaccination on rotavirus gastroenteritis in children.
There are several possible explanations. First, a lack of
association in the absence of selection bias is expected as
pentavalent vaccine should confer no immunologic pro-
tection against rotavirus disease. Therefore, it is possible
that there was no selection bias. Second, as mentioned,
our study had very limited power due to the low numbers
of both case and control children who received no penta-
valent doses. Confidence intervals around VE estimates
were very wide and included 1 for all evaluable control
groups. Sham case-control studies, like real ones of vac-
cine effectiveness, are not useful in settings of extremely
high vaccine coverage. Third, our study might have been
biased because many children were excluded from the
analysis because they did not have their vaccination cards
available and/or had unknown vaccination status and this
percentage varied between cases and controls. If these
children systematically tended to be more or less vacci-
nated, we might have missed an association between
pentavalent vaccine and rotavirus AGE.
A similar approach to quantifying bias in case-control
studies is the so-called “bias-indicator” study in which
the cases are children hospitalized with non-rotavirus
AGE, a syndrome for which rotavirus vaccine should have
no protective efficacy so that any association between the
vaccine and case-status is likely due to selection bias
[6,27]. Bias-indicator studies are a different type of sham
case-control study than we performed, in that the sham is
not the exposure (i.e. vaccine) but rather the outcome
(i.e. type of gastroenteritis). This approach was taken in
evaluations of effectiveness of oral cholera vaccine in
Mozambique and rotavirus vaccine in the U.S., both indi-
cating no measurable selection bias [27,28]. The advantage
of the bias-indicator approach is that it can be done
contemporaneously with an actual case-control study of
rotavirus AGE cases, which cannot be done for a sham
case-control study like ours due to the co-administration
of most EPI vaccines.
We found almost a third of children received the sec-
ond and third pentavalent doses late. Late vaccination
could have implications for rotavirus vaccine, as young
infants who are unvaccinated are at the greatest risk of
severe dehydration from rotavirus, particularly early in
introduction of vaccine before herd protection occurs
[23]. In addition, concerns persist about increased abso-
lute risk of intussusception among children given late
rotavirus vaccination, although WHO acknowledges that
the risk of severe rotavirus disease outweighs any poten-
tial increased risk of intussusception among late vaccines
[29-31]. Emphasis not just on vaccination, but on timely
vaccination, is important in developing countries, where
median ages of vaccination tend to be weeks to months
behind schedule [32]. Moreover, for the case-control
study, late vaccination could bias towards increased like-
lihood of vaccination among controls if the age-matching
window is too wide. In this study, we allowed children to
be matched who were up to 60 days older than the case,
which is probably too wide; we will decrease that window
for age-matching in the real case-control study.
Conclusions
Monitoring the impact and performance of new vaccines,
like rotavirus vaccine, in routine immunization programs is
important for countries and can be used to advocate fur-
ther support for the immunization program. Case-control
studies remain one of the more accessible methods for
such evaluations, despite their limitations. The findings
from this sham case-control study will enable future
rotavirus vaccine case-control studies in Kenya to be
designed more efficiently. Sham case-control studies of
VE or pilot studies of existing vaccination patterns in
communities should be considered prior to the start of
other case-control studies of the target vaccine to assess
the existence of selection bias and improve the study
design and efficiency.
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